EP3330258A4 - Dérivé 1,3,5-triazine et sa méthode d'utilisation - Google Patents

Dérivé 1,3,5-triazine et sa méthode d'utilisation Download PDF

Info

Publication number: EP3330258A4
Authority: EP; European Patent Office
Prior art keywords: same; triazine derivative; triazine; derivative
Prior art date: 2015-07-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP16829878.4A

Other languages

German (de)

English (en)

Other versions

EP3330258A1 (fr

EP3330258B1 (fr

Inventor

Na Zhao

Shulong Wang

Xijie Liu

Yuandong Hu

Hui Zhang

Hong Luo

Yong Peng

Yongxin Han

Xiquan Zhang

Hongjiang Xu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Centaurus Biopharma Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Lianyungang Runzhong Pharmaceutical Co Ltd

Original Assignee

Centaurus Biopharma Co Ltd

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Lianyungang Runzhong Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-30

Filing date

2016-07-29

Publication date

2019-01-02

2016-07-29 Application filed by Centaurus Biopharma Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd filed Critical Centaurus Biopharma Co Ltd

2018-06-06 Publication of EP3330258A1 publication Critical patent/EP3330258A1/fr

2019-01-02 Publication of EP3330258A4 publication Critical patent/EP3330258A4/fr

2021-07-14 Application granted granted Critical

2021-07-14 Publication of EP3330258B1 publication Critical patent/EP3330258B1/fr

Status Active legal-status Critical Current

2036-07-29 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP16829878.4A 2015-07-30 2016-07-29 Dérivé 1,3,5-triazine et sa méthode d'utilisation Active EP3330258B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201510459126		2015-07-30
PCT/CN2016/092254 WO2017016513A1 (fr)	2015-07-30	2016-07-29	Dérivé 1,3,5-triazine et sa méthode d'utilisation

Publications (3)

Publication Number	Publication Date
EP3330258A1 EP3330258A1 (fr)	2018-06-06
EP3330258A4 true EP3330258A4 (fr)	2019-01-02
EP3330258B1 EP3330258B1 (fr)	2021-07-14

Family

ID=57884121

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16829878.4A Active EP3330258B1 (fr)	2015-07-30	2016-07-29	Dérivé 1,3,5-triazine et sa méthode d'utilisation

Country Status (16)

Country	Link
US (1)	US10745383B2 (fr)
EP (1)	EP3330258B1 (fr)
JP (1)	JP6786086B2 (fr)
KR (1)	KR102303011B1 (fr)
CN (2)	CN107922358B (fr)
AU (1)	AU2016299092B2 (fr)
CA (1)	CA2993687C (fr)
DK (1)	DK3330258T3 (fr)
ES (1)	ES2881695T3 (fr)
HK (1)	HK1246292A1 (fr)
HU (1)	HUE056537T2 (fr)
PT (1)	PT3330258T (fr)
RU (1)	RU2724333C2 (fr)
TW (1)	TWI722004B (fr)
WO (1)	WO2017016513A1 (fr)
ZA (1)	ZA201801301B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10961222B2 (en)	2016-07-21	2021-03-30	Nanjing Sanhome Pharmaceutical Co., Ltd.	Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof
JP7111725B2 (ja)	2017-01-22	2022-08-02	正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司	１，３，５－トリアジン誘導体の塩およびその結晶、その製造方法、医薬組成物、ならびにそれらの使用
CN109265444B (zh) *	2017-07-17	2022-03-11	南京圣和药业股份有限公司	取代的三嗪类idh抑制剂的光学异构体及其应用
CN109467538A (zh)	2017-09-07	2019-03-15	和记黄埔医药（上海）有限公司	环烯烃取代的杂芳环类化合物及其用途
CN110054614B (zh) *	2018-01-19	2021-12-28	南京圣和药业股份有限公司	三嗪类idh抑制剂的可药用盐及其制备方法
CN110054615B (zh) *	2018-01-19	2021-06-15	南京圣和药业股份有限公司	三嗪类idh抑制剂甲磺酸盐的晶型
CN110054616B (zh) *	2018-01-19	2021-11-23	南京圣和药业股份有限公司	三嗪类idh抑制剂的制备方法
US12097204B2 (en)	2018-09-03	2024-09-24	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Solid pharmaceutical composition containing 1,3,5-triazine derivative or salt thereof
KR20210124569A (ko) *	2020-04-03	2021-10-15	주식회사 하임바이오	암 치료를 위한 신규 화합물 및 이를 포함하는 조성물
CN116209655A (zh) *	2020-11-09	2023-06-02	贝达药业股份有限公司	突变型idh1和idh2抑制剂及其应用
WO2023134686A1 (fr) *	2022-01-11	2023-07-20	正大天晴药业集团股份有限公司	Procédé de préparation d'un dérivé de 1,3,5-triazine
WO2023174235A1 (fr) *	2022-03-15	2023-09-21	贝达药业股份有限公司	Inhibiteur d'idh1 et d'idh2 mutantes et son application
WO2024008138A1 (fr) *	2022-07-07	2024-01-11	正大天晴药业集团股份有限公司	Combinaison pharmaceutique d'un dérivé de 1,3,5-triazine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1001665A (en) *	1961-06-05	1965-08-18	American Cyanamid Co	Triazine derivatives and process for their preparation
JP3051896B2 (ja) *	1991-03-20	2000-06-12	富士写真フイルム株式会社	ハロゲン化銀写真感光材料
US7919487B2 (en) *	2004-11-10	2011-04-05	Synta Pharmaceuticals Corporation	Heteroaryl compounds
US20060235098A1 (en)	2005-04-19	2006-10-19	Burdeniuc Juan J	Polyurethane foams made with blowing catalyst compositions containing primary hydroxyl groups and high ethylenediamine backbones
NZ606660A (en)	2010-07-20	2014-11-28	Vestaron Corp	Insecticidal triazines and pyrimidines
NZ627096A (en) *	2012-01-06	2017-02-24	Agios Pharmaceuticals Inc	Triazinyl compounds and their methods of use
WO2015003360A2 (fr)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Composés thérapeutiquement actifs et leurs méthodes d'utilisation
CN110386922A (zh)	2013-08-02	2019-10-29	安吉奥斯医药品有限公司	治疗活性化合物及其使用方法
US9975878B2 (en) *	2013-11-21	2018-05-22	Ptc Therapeutics, Inc.	Substituted triazine BMI-1 inhibitors

2016
- 2016-07-29 CN CN201680043893.5A patent/CN107922358B/zh active Active
- 2016-07-29 CA CA2993687A patent/CA2993687C/fr active Active
- 2016-07-29 CN CN202110544440.3A patent/CN113307794A/zh active Pending
- 2016-07-29 AU AU2016299092A patent/AU2016299092B2/en active Active
- 2016-07-29 DK DK16829878.4T patent/DK3330258T3/da active
- 2016-07-29 US US15/748,795 patent/US10745383B2/en active Active
- 2016-07-29 TW TW105124242A patent/TWI722004B/zh active
- 2016-07-29 ES ES16829878T patent/ES2881695T3/es active Active
- 2016-07-29 EP EP16829878.4A patent/EP3330258B1/fr active Active
- 2016-07-29 WO PCT/CN2016/092254 patent/WO2017016513A1/fr active Application Filing
- 2016-07-29 RU RU2018105614A patent/RU2724333C2/ru active
- 2016-07-29 JP JP2018504253A patent/JP6786086B2/ja active Active
- 2016-07-29 PT PT168298784T patent/PT3330258T/pt unknown
- 2016-07-29 KR KR1020187005756A patent/KR102303011B1/ko active IP Right Grant
- 2016-07-29 HU HUE16829878A patent/HUE056537T2/hu unknown
2018
- 2018-02-26 ZA ZA2018/01301A patent/ZA201801301B/en unknown
- 2018-05-07 HK HK18105822.3A patent/HK1246292A1/zh unknown

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
ZA201801301B (en)	2020-07-29
AU2016299092A1 (en)	2018-02-22
TWI722004B (zh)	2021-03-21
KR20180031036A (ko)	2018-03-27
PT3330258T (pt)	2021-08-19
AU2016299092B2 (en)	2020-08-20
CA2993687C (fr)	2023-09-26
WO2017016513A1 (fr)	2017-02-02
RU2018105614A (ru)	2019-08-29
HK1246292A1 (zh)	2018-09-07
ES2881695T3 (es)	2021-11-30
CN107922358B (zh)	2021-05-07
JP6786086B2 (ja)	2020-11-18
TW201704224A (zh)	2017-02-01
US20190062308A1 (en)	2019-02-28
CN107922358A (zh)	2018-04-17
EP3330258A1 (fr)	2018-06-06
RU2018105614A3 (fr)	2019-11-20
US10745383B2 (en)	2020-08-18
KR102303011B1 (ko)	2021-09-16
EP3330258B1 (fr)	2021-07-14
CA2993687A1 (fr)	2017-02-02
DK3330258T3 (da)	2021-08-16
CN113307794A (zh)	2021-08-27
RU2724333C2 (ru)	2020-06-23
HUE056537T2 (hu)	2022-02-28
JP2018521104A (ja)	2018-08-02
BR112018001780A2 (pt)	2018-09-11

Publication	Publication Date	Title
HK1246292A1 (zh)	2018-09-07	1，3，5-三嗪衍生物及其使用方法
HK1254654A1 (zh)	2019-07-26	4，6-亞嘧啶基衍生物及其用途
EP3325966A4 (fr)	2019-01-02	Puces, détecteurs et leurs procédés de fabrication et d'utilisation
EP3138839A4 (fr)	2018-01-03	Dérivé de pyrimidone ou de pyridone, procédé de préparation associé et application correspondante
EP3268362A4 (fr)	2018-08-15	Pyridines substituées et leurs utilisations
EP3345906A4 (fr)	2020-11-04	2-arylamino pyridine, dérivé de pyridine ou de triazine, leur procédé de préparation et leur utilisation
EP3246327A4 (fr)	2018-06-20	Dérivé 3-acétylényle-pyrazole-pyrimidine, méthode de préparation et utilisations correspondantes
EP3519572A4 (fr)	2020-06-17	Composés et procédés pour réduire l'expression de tau
EP3258372A4 (fr)	2018-12-19	Procédé de gravure et système de gravure
EP3309138A4 (fr)	2018-07-11	Procédé de coproduction de 2,3,3,3-tétrafluoropropylène et de 1,3,3,3-tétrafluoropropylène
EP3450440A4 (fr)	2019-12-25	Dérivé de benzotriazole, procédé de fabrication associé et son utilisation
EP3284320A4 (fr)	2018-11-14	Système de gradation vers le chaud et procédé pour l'utiliser
EP3556769A4 (fr)	2021-03-03	Dérivé de polyximine, procédé de préparation et application associés
EP3552017A4 (fr)	2020-06-24	Composés, compositions et méthodes
GB201600142D0 (en)	2016-02-17	Attachment assembly,parts for same,and method of using same
EP3383401A4 (fr)	2019-05-01	Dérivés de thiéno-pyrimidine et utilisations de ceux-ci
EP3297498A4 (fr)	2019-02-20	Dispositif de suspension et procédé
EP3381915A4 (fr)	2019-07-17	Dérivé de composé lactame et son application
EP3354648A4 (fr)	2019-03-20	Dérivé de coumarine 4-substitué, son procédé de préparation et d'utilisation
EP3416536A4 (fr)	2019-11-13	Guide de type winguide et son procédé d'utilisation
EP3360863A4 (fr)	2019-06-19	Dérivé étomidate et intermédiaire, procédé de préparation et utilisation de ce dernier
EP3334730A4 (fr)	2018-12-26	Pyrrolomycines et leurs procédés d'utilisation
EP3263572A4 (fr)	2018-07-25	Procédé de production de kakéromycine et de ses dérivés
EP3281945A4 (fr)	2019-01-23	Dérivé d'acide phillygénine glucuronique, son procédé de préparation et son application
EP3256686A4 (fr)	2018-10-10	Système et procédé d'abandon de puits

Legal Events

Date	Code	Title	Description
2017-02-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-05-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-05-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-06-06	17P	Request for examination filed	Effective date: 20180228
2018-06-06	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-06-06	AX	Request for extension of the european patent	Extension state: BA ME
2018-11-07	DAV	Request for validation of the european patent (deleted)
2018-11-07	DAX	Request for extension of the european patent (deleted)
2019-01-02	A4	Supplementary search report drawn up and despatched	Effective date: 20181204
2019-01-02	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 251/26 20060101ALI20181126BHEP Ipc: A61P 35/00 20060101ALI20181126BHEP Ipc: A61K 31/53 20060101ALI20181126BHEP Ipc: C07D 251/18 20060101AFI20181126BHEP
2020-05-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-06-17	17Q	First examination report despatched	Effective date: 20200515
2020-09-29	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-02-11	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2021-02-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2021-03-10	INTG	Intention to grant announced	Effective date: 20210212
2021-06-09	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2021-06-11	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2021-06-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2021-07-14	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-07-14	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2021-07-28	RAP4	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO.,LTD Owner name: LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. Owner name: CENTAURUS BIOPHARMA CO., LTD.
2021-08-04	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2021-08-05	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602016060703 Country of ref document: DE
2021-08-10	REG	Reference to a national code	Ref country code: FI Ref legal event code: FGE
2021-08-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1410553 Country of ref document: AT Kind code of ref document: T Effective date: 20210815
2021-08-16	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20210810
2021-08-18	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2021-08-19	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 3330258 Country of ref document: PT Date of ref document: 20210819 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20210812
2021-08-24	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2021-11-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2021-11-30	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2881695 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211130
2021-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1410553 Country of ref document: AT Kind code of ref document: T Effective date: 20210714
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211014 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211014 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714
2022-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211015
2022-02-28	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E056537 Country of ref document: HU
2022-04-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602016060703 Country of ref document: DE
2022-05-20	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2022-05-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210729 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714
2022-06-22	26N	No opposition filed	Effective date: 20220419
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230601
2023-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20230606 Year of fee payment: 8
2023-10-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20230726 Year of fee payment: 8
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714
2024-07-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240627 Year of fee payment: 9
2024-07-18	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20240627 Year of fee payment: 9
2024-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20240621 Year of fee payment: 9
2024-08-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20240626 Year of fee payment: 9
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210714
2024-09-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20240627 Year of fee payment: 9
2024-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240625 Year of fee payment: 9 Ref country code: FI Payment date: 20240712 Year of fee payment: 9
2024-10-11	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20240712 Year of fee payment: 9
2024-10-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PT Payment date: 20240718 Year of fee payment: 9
2024-10-15	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20240703 Year of fee payment: 9
2024-10-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20240807 Year of fee payment: 9 Ref country code: CH Payment date: 20240801 Year of fee payment: 9
2024-10-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HU Payment date: 20240716 Year of fee payment: 9